llumina and Roche have signed a 15-year, non-exclusive collaboration agreement designed to realize next-generation sequencing's potential to transform cancer risk prediction, detection, diagnosis, treatment, and monitoring . . .
- Cancer
- Molecular Diagnostics/In vitro Diagnostics
- Companion Diagnostics
- OMICs
- Sequencing
- Next-Generation Sequencing
- GEN Edge
- Illumina
- Roche
Illumina, Roche Launch NGS-Based Cancer Diagnostics Partnership
15-year agreement designed to realize NGS’ potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring.
Illumina and Roche have signed a 15-year, non-exclusive collaboration agreement designed to realize next-generation sequencing's potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring. [Roche]
